34.14 0.00 (0.00%)
After hours: 7:59PM EDT
|Bid||33.40 x 1800|
|Ask||0.00 x 1000|
|Day's Range||32.38 - 34.22|
|52 Week Range||11.65 - 41.70|
|PE Ratio (TTM)||1.86|
|Earnings Date||Nov 5, 2018 - Nov 9, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||26.41|
WASHINGTON/NEW YORK, Aug 16 (Reuters) - The Trump administration on Thursday proposed that U.S. drugmakers cut production quotas of the six most abused opioids by 10 percent next year to fight a nationwide addiction crisis. In a statement, the U.S. Justice Department and Drug Enforcement Administration (DEA) said the proposed cut would be in keeping with President Donald Trump's effort to cut opioid prescription fills by one-third within three years. Trump on Thursday also pressed U.S. Attorney General Jeff Sessions to sue drug manufacturers over the opioid crisis.
In its Q2 2018 earnings conference call, Endo International (ENDP) raised its 2018 adjusted EBITDA guidance from $1.2 billion–$1.3 billion to $1.27 billion–$1.33 billion. It expects its adjusted gross margin to be 68.5%–69.5%, which is higher than its previously projected range of 67%–68%. Wall Street analysts have projected Endo International’s 2018 adjusted diluted EPS at $2.50, which would be a YoY decline of 34.4%.
In the second quarter, Endo International (ENDP) reported revenues of $715 million, which is a YoY (year-over-year) decline of 18.4%. Additionally, the discontinuation of commercialization of certain generic pharmaceutical products in the US market, competitive pressures, and the divestitures of Grupo Farmacéutico Somar and Litha Healthcare Group had negative impacts on Q2 revenues. To know more about the performance of Endo International stock after its Q2 2018 earnings release, be sure to read Why Endo International Stock Soared after Q2 Results.
STAINES-UPON-THAMES, United Kingdom , Aug. 10, 2018 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty pharmaceutical company, will present on Wednesday, Sept. 5, 2018 ...
-- "Predictors of Opioid-Free Analgesia for Management of Acute Post-Surgical Pain in the U.S." Finds Patients Most Likely to Receive Opioid-Free Analgesia Were Older or Had Neurological Disorders, ...
Mallinckrodt (MNK) surges following earnings and sales beat in the second quarter. Increase in annual guidance is impressive as well.
Raymond James downgraded Mallinckrodt Public Limited Company (NYSE: MNK ) on valuation after the drugmaker's second-quarter report. The Analyst Raymond James analyst Elliot Wilbur downgraded Mallinckrodt ...
On August 7, Mallinckrodt (MNK) reported revenues of ~$631.7 million for the second quarter, which is ~5.3% growth YoY (year-over-year) on a reported basis and 5.0% on a constant currency basis. The company reported non-GAAP EPS of $1.78, which is a rise of 30.9% YoY. The company beat Wall Street analysts’ revenue and non-GAAP EPS estimates for the second quarter by $11.31 million and $0.30, respectively.
MARKET PULSE Mallinckrodt PLC (MNK) has been downgraded from outperform to market perform by Raymond James, as "we see limited possibilities for further meaningful outperformance given longer-term risks to key portfolio products," analyst Elliot Wilbur said in the Wednesday note.
The product has been criticized for its high price, or nearly $40,000 a year, and its effectiveness has been questioned.
The health insurer's $54 billion deal to buy pharmacy benefits manager Express Scripts ESRX will be opposed by activist investor Carl Icahn , who issued an open letter to Cigna shareholders. Icahn calls the deal a "folly" and that it carries a "ridiculous" price tag, and adds that Amazon.com AMZN represents an "existential threat" to pharmacy benefit managers. Mallinckrodt MNK – The British drugmaker earned an adjusted $1.78 per share for its latest quarter, 30 cents a share above consensus estimates.
MARKET PULSE Shares of Mallinckrodt PLC (mnk) shot up 9.2% toward a nine-month high in premarket trade Tuesday, after the pharmaceutical products company beat second-quarter profit and sales expectations, and raised its full-year outlook.
The Surrey, Britain-based company said it had net income of 19 cents per share. Earnings, adjusted for one-time gains and costs, were $1.78 per share. The results surpassed Wall Street expectations. The ...
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Mallinckrodt Plc (NYSE: MNK ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 8:30:00 AM Eastern Time. To ...
-- Net sales of $631.7 million , up 5.3%, or 5.0% on a constant-currency basis -- -- GAAP(1) diluted loss per share from continuing operations of $0.34 , adjusted diluted earnings per share of $1.78 -- ...
NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Major U.S. markets closed higher on Friday and ended the week on a positive note, as outstanding corporate earnings offsets ongoing trade spats. The Dow Jones ...
STAINES-UPON-THAMES, United Kingdom, Aug. 6, 2018 /PRNewswire/ -- Mallinckrodt plc (MNK), a leading global specialty pharmaceutical company, today announced it has formed a collaborative research partnership with Washington University School of Medicine in St. Louis, a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. The company will fund up to $10 million in research grants over a five-year period, and expects the collaborative initiative to result in multiple research programs, with a particular focus on rare diseases.